ECSP034658A - Combinacion terapeutica de amlodipina y benazepril/benazeprilato - Google Patents
Combinacion terapeutica de amlodipina y benazepril/benazeprilatoInfo
- Publication number
- ECSP034658A ECSP034658A EC2003004658A ECSP034658A ECSP034658A EC SP034658 A ECSP034658 A EC SP034658A EC 2003004658 A EC2003004658 A EC 2003004658A EC SP034658 A ECSP034658 A EC SP034658A EC SP034658 A ECSP034658 A EC SP034658A
- Authority
- EC
- Ecuador
- Prior art keywords
- milligrams
- pharmaceutically acceptable
- benazepril
- angiotesin
- corresponds
- Prior art date
Links
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 title abstract 2
- 229960004530 benazepril Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000005541 ACE inhibitor Substances 0.000 abstract 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000528 amlodipine Drugs 0.000 abstract 1
- 229960003619 benazepril hydrochloride Drugs 0.000 abstract 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 abstract 1
- 229960004067 benazeprilat Drugs 0.000 abstract 1
- MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere en especial al uso de una combinación que comprende: (1) un inhibidor de la enzima convertidora de angiotesina, seleccionado a partir del grupo que consiste en benazepril, benazeprilato, y sales farmacéuticamente aceptables de los mismos, y (2) amlodipina o una sal farmacéuticamente aceptable de la misma, para la fabricación de un medicamento para el tratamiento o la prevención o demora de progreso de una condición seleccionada a partir del grupo que consiste en hipertensión, insuficiencia cardíaca congestiva, angina, infarto de miocardia, asteriosclerosis, nefropatía diabética, mioatía cardíaca diabética, insuficiencia renal, vasculopatía periférica, hipertrofía ventricular izquierda, disfunción cognoscitiva, cerebrovasculopatía relacionada con la presión sanguinea, embolia, enfermedad pulmonar, y dolor de cabeza; en donde: (i) la cantidad de amplodipina o una sal farmaceúticamente aceptable de la misma, corresponde a de aproximadamente 6 miligramos a aproximadamente 40 miligramos de la base libre y (ii) la cantidad del inhibidor de la enzima convertidora de angiotesina o una sal farmacéuticamente aceptable del mismo, corresponde a de aproximadamente 20 miligramos a aproximadamente 160 miligramos de clorhidrato de benazepril
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/034246 WO2002049645A1 (en) | 2000-12-18 | 2000-12-18 | Therapeutic combination of amlodipine and benazepril |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034658A true ECSP034658A (es) | 2003-07-25 |
Family
ID=21742073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004658A ECSP034658A (es) | 2000-12-18 | 2003-06-17 | Combinacion terapeutica de amlodipina y benazepril/benazeprilato |
Country Status (26)
| Country | Link |
|---|---|
| EP (3) | EP1365761A1 (es) |
| JP (3) | JP2004516266A (es) |
| KR (3) | KR20040007420A (es) |
| CN (2) | CN1461218A (es) |
| AT (1) | ATE338549T1 (es) |
| AU (4) | AU2001225816B2 (es) |
| BR (2) | BR0017386A (es) |
| CA (2) | CA2432638A1 (es) |
| CY (1) | CY1106275T1 (es) |
| CZ (2) | CZ20031678A3 (es) |
| DE (1) | DE60122928T2 (es) |
| DK (1) | DK1345607T3 (es) |
| EC (1) | ECSP034658A (es) |
| ES (1) | ES2272565T3 (es) |
| HU (2) | HUP0302455A3 (es) |
| IL (4) | IL156136A0 (es) |
| MX (2) | MXPA03005462A (es) |
| NO (2) | NO20032766L (es) |
| NZ (1) | NZ526467A (es) |
| PL (2) | PL362252A1 (es) |
| PT (1) | PT1345607E (es) |
| RU (1) | RU2292206C2 (es) |
| SI (1) | SI1345607T1 (es) |
| SK (2) | SK7652003A3 (es) |
| WO (2) | WO2002049645A1 (es) |
| ZA (1) | ZA200304514B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0214383A (pt) * | 2001-11-23 | 2004-11-03 | Solvay Pharm Gmbh | Tratamento de hipertonia durante a fase aguda do ataque de apoplexia |
| US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| CN1859913A (zh) | 2003-04-25 | 2006-11-08 | 美国诺华卡迪亚公司 | 改善肾功能损伤个体多尿症的方法 |
| KR20060120126A (ko) * | 2003-10-20 | 2006-11-24 | 노파르티스 아게 | 심혈관계 이환상태를 감소시키기 위한 베나제프릴 및암로디핀 |
| WO2005074927A1 (en) * | 2004-02-09 | 2005-08-18 | Novartis Ag | Therapeutic combination of amlodipine and benazepril/ benazeprilat for the treatment of hypertension |
| WO2005079772A2 (en) * | 2004-02-18 | 2005-09-01 | Sepracor Inc. | Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| US20080268049A1 (en) * | 2005-02-11 | 2008-10-30 | Dhaliwal Mona | Stable Solid Dosage Forms of Amlodipine and Benazepril |
| WO2006092732A2 (en) * | 2005-03-04 | 2006-09-08 | Aurobindo Pharma Ltd | Stable solid dosage form of antihypertensive agent |
| MX2007011119A (es) | 2005-03-15 | 2007-11-14 | Lupin Ltd | Composiciones farmaceuticas de amlodipino y benazepril. |
| EP1930008A1 (en) * | 2005-09-28 | 2008-06-11 | Teva Pharmaceutical Industries Ltd | Sable composition of benazepril hydrochloride |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| JP2009508948A (ja) * | 2005-09-28 | 2009-03-05 | テバ ファーマシューティカル インダストリーズ リミティド | アムロジピンベシレート及びベナゼプリル塩酸塩の安定した組合わせ |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| IT1398168B1 (it) * | 2010-02-16 | 2013-02-14 | Chiesi Farma Spa | Uso di ingredienti attivi in combinazione per il trattamento delle complicanze del diabete. |
| WO2011161223A2 (en) | 2010-06-23 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts |
| CN102389431A (zh) * | 2011-09-28 | 2012-03-28 | 济南龙华医药技术有限公司 | 一种含有盐酸贝尼地平和盐酸贝那普利的复方制剂及其应用 |
| RU2014129508A (ru) * | 2011-12-21 | 2016-02-10 | Новартис Тиргезундхайт АГ | Новая комбинация |
| US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| JP2015529206A (ja) * | 2012-08-25 | 2015-10-05 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Ｇａｐｄｈカスケードインヒビター化合物ならびに使用の方法および精神病を含むストレス誘導障害の処置 |
| AU2014292086B2 (en) | 2013-07-19 | 2019-08-08 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| MX375936B (es) | 2013-12-04 | 2025-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Composiciones farmaceuticas mejoradas de pimobendan. |
| EP3434284A4 (en) * | 2016-03-24 | 2019-11-13 | Daiichi Sankyo Company, Limited | MEDICINE FOR THE TREATMENT OF KIDNEY DISEASE |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| PL3541807T3 (pl) | 2016-11-16 | 2022-01-17 | H. Lundbeck A/S | Krystaliczna postać inhibitora magl |
| CA3043609A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162802A (en) * | 1992-03-10 | 2000-12-19 | Papa; Joseph | Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor |
| EP0804229B1 (en) * | 1995-03-16 | 2003-03-26 | Pfizer Inc. | Use of amlodipine, a salt thereof or felodipin in combination with an ace inhibitor in the manufacture of a medicament for the treatment of nonischemic congestive heart failure |
| KR19980703647A (ko) * | 1995-04-07 | 1998-12-05 | 베르너발데크 | 베나제프릴 또는 베나제프릴라트 및 발사르탄을 함유하는조성물 |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
-
2000
- 2000-12-18 AU AU2001225816A patent/AU2001225816B2/en not_active Ceased
- 2000-12-18 CA CA002432638A patent/CA2432638A1/en not_active Abandoned
- 2000-12-18 MX MXPA03005462A patent/MXPA03005462A/es not_active Application Discontinuation
- 2000-12-18 JP JP2002550985A patent/JP2004516266A/ja active Pending
- 2000-12-18 AU AU2581601A patent/AU2581601A/xx active Pending
- 2000-12-18 CN CN00820080A patent/CN1461218A/zh active Pending
- 2000-12-18 PL PL00362252A patent/PL362252A1/xx not_active Application Discontinuation
- 2000-12-18 EP EP00989288A patent/EP1365761A1/en not_active Withdrawn
- 2000-12-18 CZ CZ20031678A patent/CZ20031678A3/cs unknown
- 2000-12-18 KR KR10-2003-7007578A patent/KR20040007420A/ko not_active Withdrawn
- 2000-12-18 IL IL15613600A patent/IL156136A0/xx unknown
- 2000-12-18 BR BR0017386-0A patent/BR0017386A/pt not_active Application Discontinuation
- 2000-12-18 SK SK765-2003A patent/SK7652003A3/sk not_active Application Discontinuation
- 2000-12-18 WO PCT/US2000/034246 patent/WO2002049645A1/en not_active Ceased
- 2000-12-18 HU HU0302455A patent/HUP0302455A3/hu unknown
-
2001
- 2001-12-17 KR KR1020097004242A patent/KR20090033914A/ko not_active Ceased
- 2001-12-17 ES ES01992150T patent/ES2272565T3/es not_active Expired - Lifetime
- 2001-12-17 MX MXPA03005463A patent/MXPA03005463A/es active IP Right Grant
- 2001-12-17 EP EP06003150A patent/EP1674099A1/en not_active Withdrawn
- 2001-12-17 BR BR0116228-4A patent/BR0116228A/pt not_active IP Right Cessation
- 2001-12-17 KR KR10-2003-7007754A patent/KR20030061840A/ko not_active Ceased
- 2001-12-17 CN CNA018208398A patent/CN1481241A/zh active Pending
- 2001-12-17 AT AT01992150T patent/ATE338549T1/de active
- 2001-12-17 PL PL01360989A patent/PL360989A1/xx not_active Application Discontinuation
- 2001-12-17 HU HU0302456A patent/HUP0302456A3/hu unknown
- 2001-12-17 DE DE60122928T patent/DE60122928T2/de not_active Revoked
- 2001-12-17 JP JP2002550986A patent/JP2004519440A/ja not_active Withdrawn
- 2001-12-17 IL IL15626701A patent/IL156267A0/xx unknown
- 2001-12-17 CA CA002432282A patent/CA2432282A1/en not_active Abandoned
- 2001-12-17 WO PCT/US2001/048808 patent/WO2002049646A1/en not_active Ceased
- 2001-12-17 PT PT01992150T patent/PT1345607E/pt unknown
- 2001-12-17 NZ NZ526467A patent/NZ526467A/en unknown
- 2001-12-17 DK DK01992150T patent/DK1345607T3/da active
- 2001-12-17 CZ CZ20031677A patent/CZ301424B6/cs not_active IP Right Cessation
- 2001-12-17 RU RU2003121019/15A patent/RU2292206C2/ru not_active IP Right Cessation
- 2001-12-17 AU AU2002232620A patent/AU2002232620B9/en not_active Ceased
- 2001-12-17 SK SK764-2003A patent/SK7642003A3/sk not_active Application Discontinuation
- 2001-12-17 AU AU3262002A patent/AU3262002A/xx active Pending
- 2001-12-17 SI SI200130662T patent/SI1345607T1/sl unknown
- 2001-12-17 EP EP01992150A patent/EP1345607B1/en not_active Revoked
-
2003
- 2003-06-10 ZA ZA200304514A patent/ZA200304514B/xx unknown
- 2003-06-17 NO NO20032766A patent/NO20032766L/no not_active Application Discontinuation
- 2003-06-17 EC EC2003004658A patent/ECSP034658A/es unknown
- 2003-06-17 NO NO20032765A patent/NO20032765L/no not_active Application Discontinuation
-
2006
- 2006-11-30 CY CY20061101728T patent/CY1106275T1/el unknown
-
2008
- 2008-04-10 IL IL190801A patent/IL190801A0/en unknown
- 2008-04-10 IL IL190802A patent/IL190802A0/en unknown
-
2009
- 2009-10-09 JP JP2009235225A patent/JP2010043111A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190802A0 (en) | Therapeutic combination of amlodipine and benazepril/benazeprilat | |
| Thadani | Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance | |
| EA009983B1 (ru) | Лекарственное средство для профилактики и лечения артериосклероза и гипертензии | |
| JP2005532330A (ja) | Ｄｐｐｉｖ阻害剤および心臓血管化合物の組み合わせ | |
| CO6251256A2 (es) | Sales del inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4il)1h-pirazol-1-il)-3-ciclopentilpropanitrilo | |
| CR7074A (es) | Derivados de mercaptoacetylamida y proceso para su preparacion y uso | |
| Märki et al. | Piperidine renin inhibitors: from leads to drug candidates | |
| KR100939243B1 (ko) | 포타슘 채널의 기능을 조절하는 아민 유도체, 그의제조방법 및 용도 | |
| PT1487424E (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-il-amino)fenil]-benzamida para o tratamento doenças mediadas por ang ii | |
| NO20064811L (no) | 4-(5-aminometyl-2-fluor-fenyl)-piperidin-1-yl]-(4-brom-3-metyl-5-propoksy-tiofen-2-yl)-metanonhydroklorid som en inhibitor av mastcelletryptase | |
| CN102869360B (zh) | 治疗高血压的医药组合物及方法 | |
| KR19980086748A (ko) | 당뇨성 심근증의 예방 또는 전환에 있어서 알도스 리덕타제의 억제 방법 | |
| BR0108592A (pt) | Compostos de piperazina substituìda | |
| US5798357A (en) | Agent for prophylaxis and treatment of thromboxane A2 -mediated diseases | |
| Opie | Calcium channel antagonists part III: use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications | |
| SG153644A1 (en) | Therapeutic combination of amlodipine and benazepril | |
| Monopoli et al. | Effects of antihypertensive drugs on cardiac hypertrophy | |
| RU2003121016A (ru) | Терапевтическая комбинация амлодипина и беназеприла | |
| Mealy et al. | Nolomirole Hydrochloride | |
| Ebner et al. | Clinical diferenciation of nifedipine and other calcium antagonists | |
| ECSP993240A (es) | Preparaciones de combinacion farmaceutica | |
| HK1106442A1 (en) | Association of a sinus node if, current inhibitor and a calcium inhibitor, and pharmaceutical compositions containing it |